In contrast to the STAT5 inhibitor AC-4-130 and the BMI1 inhibitor PTC596, whose efficacies were cell- and context-dependent, the MEK1 inhibitor trametinib was generally less effective in the AML cells in the presence of HS-5 stroma (Figure 3). Here, BMI1 is linked to acute myeloid leukemia.